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These guidelines are an abridged version of the
recently published guidelines for clinical practice for
reducing the risk of anaphylaxis during anaesthesia [1,
2], recently developed and implemented in France under
the auspices of the French Society for Anaesthesia and
Intensive Care (SFAR: Société Française d’Anesthésie
et de Réanimation), according to the methodological
recommendations of the French National Agency of
Evaluation in Medicine (ANAES: Agence Nationale
d’Accréditation et d’Evaluation en Santé -http://
www.anaes.fr).
These guidelines represent a consensus of experts from
a variety of disciplines (anaesthetists, allergists, biologists,
physiologists…) and were based on international science.
Their aim was to provide the most valid, widely accepted,
effective and easily teachable guidelines that current
knowledge, research and experience can provide. To
achieve this goal, experts had to answer a list of pre-
established questions. Participants used evidence-based
criteria to identify, evaluate, and appraise scientific
publications indexed in Medline, Pascal and Excerpta
Medica. All experts applied the tools and principles of
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evidence-based medicine concerning levels of evidence
and classes of recommendations recommended by the
SFAR on all proposed guidelines (Table 1). Extensive
literature analysis supporting the recommendations was
provided by experts. To increase the validity of the results
obtained, this version was reviewed by a large panel of
80 lecturers (topic experts, conference leaders, specialists
from disciplines concerned with allergy, anaesthesiology,
critical care, surgery …) for scientific accuracy, but also
for possible future effects on safety, cost, effectiveness,
and teachability. This final version, published as a full
text [2], was summarized in a short but more practical
version. This paper presents the main extracts of these
recommendations with the most relevant clinical
implications, following minor adaptations or
modifications, as suggested by a panel of experts from
ENDA (European Network for Drug Allergy) and the
EAACI interest group on drug hypersensitivity.
1. Reality of the allergic risk during
anaesthesia – incidence – morbidity –
mortality – responsible agents –
clinical picture.
1.1. The reality of the allergic risk during
anaesthesia is established on the basis of the
more than 12,000 cases of peranaesthesic
hypersensitivity reactions published in the
literature over the last 15 years (D).
1.2. Among the hypersensitivity reactions occurring
during anaesthesia, about 60% are mediated by
an IgE-dependent immunologic mechanism
(allergic reaction).
1.3. Authors from many countries have reported
cases of hypersensitivity reactions. The
majority come from France, Australia and New
Zealand, thanks to the organization established
in these countries 25 years ago for reporting
these reactions, as well as the strategy of written
and oral communication existing in medicine.
1.4. Depending on the country, hypersensitivity
reactions represent 9 to 19% of complications
associated with anaesthesia (D). The mortality
rate is about 5 to 7% (D). Morbidity is expressed
as more or less severe anoxic cerebral sequelae;
its incidence has not been quantified.
1.5. In 1996, the incidence of anaphylactic reactions
in France was estimated to be 1/13,000 general
and local or regional anaesthesia, all types of
substances included. The incidence of
anaphylaxis caused by muscle relaxants was
1/6,500 anaesthesia in which one of these drugs
was administered (D).
1.6. The agents responsible for the anaphylactic
Level I A prospective randomised study with a low positive (α) and negative (β) risk
Level II A prospective randomised study with high α risk or low or unknown power
Level III Non-randomized prospective study, must have a control group for comparisons
Level IV Non-randomized studies, historical control group
Level V Case series. Expert advice
Classes of recommendations
A 2 (or more) level I studies
B 1 level I study
C Level II study(ies)
D Level III study(ies)
E Level IV or V study(ies)
Table 1. Levels of evidence and classes of recommendations (SFAR)
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reactions occurring during anaesthesia have
been identified in 4,000 cases of anaphylaxis
published since 1980. Muscle relaxants are
involved in 62% of the total, latex in 16.5%,
hypnotics (7.4%), antibiotics (4.7%), plasma
substitutes (3.6%) and opioids in 1.9% of cases.
Allergy to local anaesthetic agents is exceptional
(0.7%). No anaphylactic reaction to inhaled
anaesthetics has been published. Various other
agents can induce anaphylaxis during
anaesthesia such as aprotinine, chlorhexidine,
protamine, papain and plasma substitutes.
1.7. The importance of each of these different
substances in causing anaphylactic reactions
appears to be identical in different countries.
1.8. The muscle relaxants most often involved in
anaphylaxis in France in 1997-1998 are, in
decreasing order of the number of cases
reported: rocuronium, suxamethonium,
atracurium and vecuronium (D). The relation
between the number of patients having had a
reaction to each of these agents and the number
of patients treated with them is the highest for
rocuronium and suxamethonium, the lowest for
atracurium, with vecuronium situated in-
between (E).
1.9. The clinical manifestations are classified in five
stages of increasing severity:
   • I - generalized cutaneous signs: erythema,
urticaria with or without angioedema
   • II - moderate multi-organ involvement, with
cutaneous signs, hypotension and severe
tachycardia, bronchial hyperreactivity (cough,
ventilatory impairment)
   • III - severe life-threatening multi-organ
involvement that requires specific treatment:
collapse, tachycardia or bradycardia, cardiac
arrhythmias, bronchospasm; the cutaneous
signs may be absent or occur only after the
arterial blood pressure recovers normal value.
   • IV - circulatory and/or respiratory arrest
   • V - death due to inefficient cardiorespiratory
resuscitation.
1.10. The clinical manifestations are more severe and
longer lasting in reactions of immunologic
origin than in pharmacologic reactions. The
clinical signs do not always fully exist and they
may be misleading. The absence of cutaneous
signs does not exclude the diagnosis of
anaphylaxis.
2. Diagnostic investigation
2.1. Every patient presenting with a hypersensitivity
reaction during anaesthesia must undergo an
immediate as well as a secondary investigation
for the causal agent, IgE-dependent mechanism
and cross-reactive sensitization if the agent is
a muscle relaxant (D).
2.2. The anaesthetist is responsible for:
2.2.1. initiating the investigation, in colla-
boration with a consulting allergist;
2.2.2. informing the patient about the nature
of the reaction and recommendations
for subsequent anaesthesias;
2.2.3. reporting the event to the phar-
macovigilance centre if a drug is
suspected to be the cause; reporting it
to the pharmacovigilance centre of the
local institution (when available) if
latex is suspected to be involved.
2.3. For patients with clinical signs suggestive of
an allergic reaction during anaesthesia, various
laboratory examinations, initiated immediately,
would be useful for the diagnosis:
2.3.1. The likelihood that the clinical
symptoms are connected to a hyper-
sensitivity reaction is substantiated by
an increased serum tryptase or plasma
histamine concentration (C), even
though a normal figure does not totally
rule out this diagnosis.
2.3.2. An obvious increase in the level of
serum tryptase (> 25 µg·L-1) is in favour
of an anaphylactic mechanism (C).
2.3.3. An increased concentration of plasma
histamine indicates in vivo histamine
release. In the case of a less severe
reaction, only a blood sample taken
very shortly after the onset of the
reaction would be informative.
2.3.4. The plasma histamine assay is not
useful in pregnant women and in
patients receiving high doses of
heparin during extra-corporeal
circulation, as in these cases plasma
histamine is undetectable (D).
2.3.5. Determination of urinary methylhis-
tamine concentration is no longer
recommended, as it is less sensitive
for diagnosis than blood histamine
and tryptase (D).
2.3.6. These assays require taking 7.5 mL
of blood in a dry tube and 7.5 mL in
an EDTA tube, as soon as possible
after the control of the clinical
situation, ideally in the hour following
the first signs of the reaction. These
tubes should be carried to the local
laboratory within 2 hours. If
impossible, they can be stored in a
refrigerator at + 4° C, but not for
longer than 12 hours. After
centrifugation, the plasma (recovered
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from above the leukocyte pellet) and
the serum should be frozen and stored
at - 20° C in several aliquots.
2.3.7. In case of a reaction after injection of
a muscle relaxant, an aliquot of serum
should be obtained and stored for
assay for quaternary ammonium ion-
specific IgE (D).
2.3.8. If the patient is at risk to die, the blood
samples should be obtained before
resuscitation is detained rather than
post-mortem.
2.3.9. Because of the potential seriousness of
the situation and the short half-life of
certain mediators, it is recommended
that a package containing tubes for the
blood samples, the blood sampling
protocol and a form for clinical data
recording are continuously available in
the operating room.
2.3.10. Quality control at a national level of
assays for histamine, tryptase and
specific IgE is worth being established.
2.4. Skin tests are best done after a delay of at least
six weeks (D). If necessary, they can be carried
out earlier, but with an increased risk of false
negative results. Therefore only positive results
can be taken into account. If the skin tests are
done before six weeks, then they should be
repeated after the sixth postoperative week.
2.4.1. Anaesthetists should identify local
allergists capable of performing the
investigations necessary to diagnose
the cause of a hypersensitivity
reaction occurring during anaesthesia.
This list should be readily available
when such a consultation is needed.
2.4.2 The investigations for allergy
diagnosis  include:
2.4.2.1. Appropriate training, expe-
rience and continuing education
providing updated knowledge of allergy
problems specific to anaesthesia of the
allergist performing the skin testing and
interpreting the results;
2.4.2.2. A supply of the products
required for the skin tests, stored under
conditions that comply with good
pharmaceutical practice (accepting that
these are not licensed products) and
with the rules of hygiene and asepsis;
2.4.2.3.  An environment permitting
rapid resuscitation in the place where
challenge tests are done.
2.4.3. Given the present state of knowledge,
skin tests (prick and intradermal
reaction) remain the golden standard
for the detection of IgE-dependent
allergies. However, they can be used
neither for the detection of allergy to
dextrans nor for the detection of
delayed hypersensitivity reactions,
which are investigated by a different
method (D).
2.4.3.1. Skin tests are done after
obtaining a detailed clinical history
and information on the chronology of
the event furnished by the anaesthetist,
accompanied by a copy of the
anaesthesia record and the results of
the laboratory tests on blood samples
obtained at the time of the reaction.
2.4.3.2. Before carrying out these
tests, the following preliminary
conditions must be met: the patient’s
informed consent must be obtained,
and drugs that are known to inhibit skin
test reactivity, such as antihistamines
and psychotropic drugs, must be
stopped several days before the test (E).
Pregnancy, young age and treatment
with beta-adrenergic blocking agents,
oral corticosteroids and inhibitors of
enzyme conversion are not
contraindications to doing skin tests.
2.4.3.3. Skin tests must include all
drugs listed in the anaesthesia record
(with the exception of inhalational
agents), as well as with latex and other
agents administered during this
procedure.
2.4.3.4. Investigation of latex as a
cause of anaphylaxis is performed by
prick test, using two different
commercial extracts (E).
2.4.3.5. Investigation of anaesthetic
agents as a cause of anaphylaxis is
performed by prick test and/or
intradermal reaction using commercial
solutions either undiluted or diluted in
aqueous phenol. Intradermal reactions
are first done with a 1/1000 dilution of
the agent, except with muscle relaxants
and morphine, for which a 10,000
dilution is used. If the first intradermal
reaction is negative, then successive
ten-fold lower dilutions are used, with
a 20-minute interval between each test.
The maximal concentrations not to be
exceeded, to avoid false positive
results, are given in Table 2 (E).
2.4.3.6. Interpretation of the skin
tests requires preliminary verification
of the normal reactivity of the patient’s
skin (E) by a negative control test
(prick or intradermal, using an equal
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volume of the solvent) and a positive
control test (prick or intradermal, with
9% codeine phosphate solution and/
or a 10 mg·mL-1 solution of histamine,
that produces a wheal with a diameter
of at least 3 mm after 20 minutes).
2.4.3.7. The place on the skin where
the tests are to be done is of no special
importance, provided that interpretation
of the results takes into account the size
of the bleb induced by the intradermal
injection of the product being tested and
the normal reactivity of the skin at the
test sites.
2.4.3.8. The criteria of a positive
prick test are the appearance after 20
minutes of an oedematous wheal with
a diameter at least 3 mm greater than
that induced by the negative control
solution and with a diameter equal to
or larger than half the diameter of the
wheal induced by the positive control
solution.
2.4.3.9. Intradermal tests are done
by injecting into the dermis 0.03 to
0.05 mL of a diluted commercial
preparation of the test substance, this
being enough to produce an injection
papule no larger than 4 mm in
diameter. The criteria for positivity of
an intradermal test are the appearance
after 20 minutes of a wheal with a
diameter of at least 8 mm and which
is also at least double the diameter of
the bleb produced by the injection.
The anaesthetic drugs used in these
tests are diluted, when necessary, in
physiologic salt solution containing
5% phenol. They can nevertheless be
stored at + 4°C for no more than 3
months, except for atracurium,
rocuronium, mivacurium and cis-
atracurium, for whom the stability has
not been established (E).
2.4.3.10. When the prick or
intradermal test with a muscle relaxant
Available agents Prick-tests Intradermal tests
INN C    Dilution MC  Dilution      MC(mg.mL-1) (mg.mL-1)       (µg.mL-1)
atracurium 10 1/10   1 1/1000 10
cis-atracurium   2 undiluted   2 1/100 20
mivacurium   2 1/10 0,2 1/1000   2
pancuronium   2 undiluted   2 1/10 200
rocuronium 10 undiluted 10 1/100 100
suxamethonium 50 1/5 10 1/500 100
vecuronium   4 undiluted   4 1/10 400
etomidate   2 undiluted   2 1/10 200
midazolam   5 undiluted   5 1/10 500
propofol 10 undiluted 10 1/10 1000
thiopental 25 undiluted 25 1/10 2500
alfentanil 0.5 undiluted 0.5 1/10 50
fentanyl 0.05 undiluted 0.05 1/10   5
morphine 10 1/10 1 1/1000 10
remifentanil 0.05 undiluted 0.05 1/10   5
sufentanil 0.005 undiluted 0.005 1/10 0.5
bupivacaine 2.5 undiluted 2.5 1/10 250
lidocaine 10 undiluted 10 1/10 1000
mepivacaine 10 undiluted 10 1/10 1000
ropivacaine   2 undiluted   2 1/10 200
Table 2. Concentrations of anaesthetic agents normally non-reactive in practice of skin tests.
INN = International Non proprietary Name;    C= concentration;    MC = maximal concentration
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is positive, investigation for cross-
reactivity with other commercialised
muscle relaxants must be done by the
intradermal route, taking into account
the maximal concentration of the drug
that must not be exceeded (Table 2).
2.4.3.11. In the case of a patient who
has had an anaphylactic reaction to a
muscle relaxant, proven by skin test,
before giving a newly commercialised
muscle relaxant to the patient it is
essential to do an intradermal test with
it to look for possible cross-
sensitization to other muscle relaxants.
The maximal concentration of this new
drug that is not to be exceeded must
first be determined in non-sensitized
healthy controls.
2.4.3.12. Before any new anaesthetic
drug is introduced on the market, their
cutaneous reactivity in healthy
volunteers should be studied in order
to standardize the skin test method and
its interpretation.
2.5. Laboratory tests
2.5.1. Assays for IgE antibodies in the
patient’s serum of the patient for
muscle relaxants (with quaternary
ammonium ions), thiopentone and
latex. The results of assays for these
specific IgEs can be helpful in the
interpretation of negative or doubtful
skin test results, especially when the
clinical signs were highly suggestive
of anaphylaxis (E). It is preferable to
use only assays with the highest
sensitivity for IgE specific for muscle
relaxants: QAS-RIA (quaternary
ammonium sepharose - radio-immuno-
assay) and PAPPC-RIA (P-
aminophenylphosphoryl-choline -
radio-immuno-assay). For anti-latex
IgE, the commercial assays are quite
satisfactory.
2.5.2. The leukocyte histamine release
assay, using the patient’s basophils, is
not the first choice  diagnostic test. In
rare cases, it might be useful as a
complement to skin tests to confirm
the diagnosis. It might also help with
the choice of a muscle relaxant for a
subsequent anaesthesia in case cross-
sensitization is found.
2.5.3. Other cellular assays based either on
flow cytometry or on the release of
sulphidoleukotrienes are not sufficiently
validated to be recommended for
routine use.
2.6. Provocation tests
2.6.1. A document designed for the patient
and containing information on the test
methods and on the risks is essential
for obtaining the patient’s informed
consent. The document containing
this information should be available
to be handed to the patient before the
tests are carried out.
2.6.2. Indications for progressive challenge
tests are limited to local anaesthetics
and latex, and they should be done
only after being certain that skin tests
are negative.
– Test with a local anaesthetic: inject 0.5 to
1.0mL of test solution undiluted and
containing no epinephrine subcutaneously
(E). The test is negative if no anaphylactic
reaction occurs during the 30 minutes
following the injection. In pregnant patients,
the test is to be done in the delivery room
30 minutes before the induction of epidural
anaesthesia (E).
– Test with latex: wearing a natural rubber
latex glove for 15 minutes. The test is
negative if there is no sign of a local allergic
reaction (urticaria) occurring within the
following 30 minutes. If the patient
experienced bronchospasm during the
course of the initial reaction, and both skin
test and provocation test are negative,
consider bronchial provocation test.
2.7. Results of the allergy investigation
2.7.1. A positive diagnosis of anaphylaxis
depends on positive skin tests,
laboratory results and coherence of
these results with the clinical history
and the anaesthesia protocol.
2.7.2. Close collaboration between the
allergist and the anaesthetist is
essential within the frame of an
allergy consultation (E).
2.7.3. A full report of the results written by
the allergist is to be addressed to the
anaesthetist. This report must be
included in the patient’s medical
records. Copies must also be sent by
the anaesthetist to the regional
pharmacovigilance centre (if available)
accompanied by a clinical description
of the reaction, and also to the patient’s
attending physician.
2.7.4. The conclusions must be transmitted
to the patient by the anaesthetist,
giving the patient a written copy of
the document. The patient should be
encouraged to carry this written
document with his identity papers. He
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should also be encouraged to wear a
bracelet (example: Medic-Alert) or a
tag signalling this allergy (E).
2.7.5. Advice concerning matters of
anaesthetic technique and indications
can only come from the anaesthetist (E).
2.7.6. When there is difficulty in interpretation
of the results of the allergy workup and
of the consequences on a subsequent
anaesthesia, appeal to a local or regional
group of reference anaesthetist who  has
had training  and is updated in the
knowledge of allergic reactions
associated with anaesthesia should be
made. A list of such specialists should
be readily available to physicians who
might     need it.
2.8. It would be desirable to ascertain regularly the
incidence of the number of allergic reactions
occurring during anaesthesia:
2.8.1. by collecting data from referral centres
and regional pharmacovigilance
centres;
2.8.2. by considering them in relation to
anaesthesia-associated mortality and
morbidity data.
3. Predisposing factors for anaphylaxis
during anaesthesia and the value of the
preanaesthetic allergy investigation.
3.1. Patients at risk for anaphylaxis during
anaesthesia.
3.1.1. Patients who are allergic to one of the
drugs or products likely to be
administered or used during anaesthesia
and for which the diagnosis had been
established by a previous allergy
investigation.
3.1.2. Patients who have shown clinical
signs suggesting an allergic reaction
during a previous anaesthetic.
3.1.3. Patients who have experienced
clinical manifestations of allergy
when exposed to latex (D), whatever
the circumstances in which this
occurred.
3.1.4. Children who have had multiple
operations, especially those with spina
bifida, because of the high rate of
sensitization to latex (D) and of the
high incidence of anaphylactic shock
caused by latex in such patients.
3.1.5. Patients who have experienced
clinical manifestations of allergy to
avocado, kiwi, banana, chestnut,
buckwheat, etc., because of the high
rate of cross-reactivity with latex (D).
3.2. Patients who are atopic (for example, those
with allergic asthma or hay fever) or those who
are allergic to a drug or other product that is
not likely to be used during the course of the
anaesthesia are not to be considered at risk for
anaphylaxis during preanaesthesia.
3.3. Preanaesthesia allergy investigation
3.3.1. Risk factors for allergy must be
investigated in a systematic manner
before every anaesthesia.
3.3.2. Concerning anaesthesia for members
of the general population, it is not
necessary to do a systematic
screening for sensitivity to drug(s),
and/or other products used in
anaesthesia. This policy is justified
by the absence of sufficient
information on the positive and
negative predictive values of allergy
skin tests and laboratory tests for
these substances in the general
population. Indeed, false negative
results and/or false positive results
can have disastrous consequences for
anaesthesia by leading to change to
an inadequate anaesthesia technique.
Because of this, the risk/benefit ratio
of such an approach is unknown.
3.3.3. In those patients who are atopic or
allergic to a drug or product that will
not be used during the course of the
anaesthesia, it is not necessary to look
for sensitivity to anaesthetic drugs or
other products that are to be used
during the course of anaesthesia.
3.3.4. For those patients who are at risk as
defined above (3.1.), an allergy
investigation looking for specific
sensitization should be proposed
before any anaesthetic procedure.
Nevertheless, no matter which tests
are used, they do not guarantee an
absolutely correct diagnosis. Indeed,
skin tests done some time after a
reaction can be negative. A work-up
done six weeks after an incident is
always preferable.
3.3.4.1. Investigations for patients in
category 3.1.1.
• Follow the conclusions of the
previous allergy investigation.
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3.3.4.2. Investigations for patients of
category 3.1.2.
Depending on the circumstances of
the surgical procedure, the course to
follow is explained in Figure 1.
3.3.4.2.1. In the well-prepared
situation, the anaesthetist
should check the previous
anaesthesia record for
evidence of the cause of the
reaction and transmit this
information to the allergist
who is going to do the tests.
• When the previous
anaesthesia record is not
available: test all the
muscle relaxants and latex
(skin tests ± specific IgE).
• When the previous
anaesthesia record is
available: test latex and the
drugs used in the previous
protocol (skin tests ±
specific IgE). In case of
local anaesthesia, perform
a progressive challenge test
(E) after ascertainment that
the skin tests are negative
(paragraph 3.4.)
• A pregnant woman at risk




the local anaesthetic agents
should be tested by the
Identified
History of hypersensitivity reaction during a previous anaesthesia
Emergency procedure Scheduled procedure





Test all muscle relaxants and latex







• either local-regional anaesthesia or general
anaesthesia without the muscle relaxants or
histamine releasing products
• test the agents used during the previous anaesthesia
procedure + latex
(prick and/or intradermal tests ± specific IgE)
• if muscle relaxant: test all the muscle relaxants
(intradermal tests)
• if local anaesthetic: skin tests
α if negative, use a subcutaneous challenge test
Not identified
yes no
Figure 1. Decisional algorithm for a patient reporting a hypersensitivity reaction during a previous anaesthesia and
who has had no allergy investigation.
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allergist, using the
intradermal route. When
the tests are negative, a
progressive challenge test
can be done in the delivery
room by the anaesthetist
before the insertion of
epidural catheter, after
having obtained informed
consent from the patient.
3.3.4.2.2. In an emergency, the
precautionary approach would
be to exclude all latex




muscle relaxants or histamine-
releasing agents.
3.3.4.3. Investigations for patients in
categories 3.1.3 to 3.1.5.
Prick test with latex ± latex-specific IgE.
4. Can prevention of allergy risk
during anaesthesia be obtained by
premedication and/or a particular
environment?
4.1. Primary prevention of sensitisation.
4.1.1. Total avoidance of contact with latex
from the first surgical procedure and
in the   medical environment of infants
with spina bifida prevents the
acquisition of latex sensitivity (E).
4.1.2. Latex particles carried by cornstarch
glove powder is the factor of
sensitization by inhalation. Reduction
of the incidence of sensitization in
professionals exposed to this powder
can be achieved by the use of non-
powdered latex gloves.
4.1.3. There is actually no way to prevent
primary sensitization to muscle
relaxants. Anaphylactic reactions to
these agents can occur in the absence
of their prior administration.
4.2. Secondary prevention for patients already
sensitized:
4.2.1. The only effective secondary preventive
measure is to identify the responsible
allergen and then completely avoid it.
When this is possible, subsequent
allergic reactions to this allergen can
be avoided (E).
4.2.2. For patients sensitized to latex, a latex-
free environment is effective for the
prevention of an anaphylactic reaction
(E). The latex-free environment must
include the operating rooms, the
postoperative recovery room and some
other sectors of the hospital. To
facilitate the transmission of the orders
for preventive measures in these
various sectors, a “check-list” provi-
ding information on management of
the patient is recommended. Every
anaesthesia service, in collaboration
with the hospital’s pharmacy, should
establish a list of latex-free medical
and surgical material, and update  it
regularly.
4.2.3. In order to identify patients sensitized
to anaesthetic drugs and/or products
planned to be administered during the
procedure, the principle of an
intravenous test dose is prescribed, as
a very low dose of allergen can induce
anaphylaxis in sensitized patients (E).
4.3. Premedication
4.3.1. For patients allergic to latex and to
drugs, premedication with an H1 anti-
histamine alone, an H2 anti-histamine
alone, a corticosteroid or association
of two or more of these drugs does
not guarantee that an anaphylactic
reaction will not occur (C, D).
4.3.2. The administration of an H1 anti-
histamine alone, or combined with an
H2 anti-histamine could prevent
bronchospasm and haemodynamic
variations caused by non-specific
histamine release (C).
4.3.3. Premedication with a monovalent
substance
4.3.2.1. Dextrans
The rate of severe reactions to
dextrans can be decreased by
administering dextran I (Promit®),
which is a monavalent inhibition of
dextran binding.
4.3.2.2. Muscle relaxants
The concept of protection with a hapten
(“haptenic protection”) including only
a single quaternary ammonium has
been used for the prevention of
anaphylaxis in some patients allergic
to muscle relaxants (E). However, in
the absence of controlled clinical
studies, such “haptenic protection”
cannot be recommended for routine
use at present.
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4.4. Special cases
4.4.1. The intravenous administration of
antibiotics for preoperative prophylaxis
should be started in the operating room
with the patient awake and being
monitored, 5 to 10 minutes before
anaesthesia induction.
4.4.2. Because there is no evidence of cross
reactivity between propofol and
muscle relaxants, the use of propofol
in patients allergic to a muscle
relaxant is not contraindicated.
5. Treatment of allergic reactions
occurring during the course of
anaesthesia
5.1. Recommendations for the treatment of allergic
reactions occurring during the course of
anaesthesia must not be established on a rigid
scheme. Treatment must be adapted to the
severity of the clinical situation, to the patient’s
history, to the associated treatment and to the
patient’s response to the emergency treatment.
It is understood that the patient is monitored
as required in any anaesthetic procedure.
5.2. General measures used in all cases (E)
5.2.1. Discontinue the administration of the
drug and/or product that is suspected
of being the causative factor.
5.2.2. Information from the surgical team
(depending on the situation: cancel,
simplify, accelerate or stop surgery).
5.2.3. Administer 100 vol% oxygen.
5.3. In grade I reactions, the measures described in
paragraph 5.2. are generally sufficient.
5.4. In more severe cases (grade II or III) (E):
5.4.1. Rapidly control the airways.
5.4.2. Administer epinephrine intravenously
by bolus in titrated doses. The initial
dose, determined as a function of the
severity of the hypotension (10 to 20
µg for grade II reactions; 100 to 200
µg for grade III reactions), to be
repeated every 1 to 2 minutes until
restoration of convenient arterial
blood pressure. In case of
ineffectiveness of this treatment, the
dose should be increased rapidly.
Intravenous perfusion at a dose of 0.05
to 0.1 µg·kg-1·min-1 might be used
instead of repeated bolus
administration of epinephrine. In case
an effective intravenous route is not
immediately available, the
intramuscular route can be used (0.3
to 0.5 mg), with injections repeated
after 5 to 10 min, depending on the
patient’s haemodynamic status. In the
same situation, the intratracheal route
can be used if the trachea is intubated,
knowing that only one third of the dose
will enter the systemic circulation.
5.4.3. Ask for help from competent staff.
5.4.4. Elevate the patient’s legs.
5.4.5. Rapidly restore the vascular volume
with isotonic cristalloid. Colloids
should replace salt solutions when the
volume of salt solution exceeds 30
mL·kg-1, avoiding the administration
of the substance or substances that are
suspected to be the cause of the
reaction.
5.4.6. In case of bronchospasm without
arterial hypotension, a beta2-
adrenergic agonist (such as
salbutamol) can be administered
through an inhalation chamber
adapted to the ventilatory circuit. In
case of resistance to this treatment, or
immediately severe reaction, the
intravenous route can be used:
administer a 100 to 200 µg bolus of
salbutamol, followed by continuous
perfusion of this drug (5 to 25 µg·min-1).
The most severe forms can be reversed
by continuous perfusion of epinephrine.
5.4.7. In pregnant women, because of the
risk of hypoperfusion of the placenta
caused by epinephrine, treatment of
the hypotension should be started with
intravenous ephedrine (10 mg,
repeated every 1 to 2 min, with a
maximum cumulative dose of 0.7
mg·kg-1). In addition, the patient
should be placed in left lateral
decubitus. In case of ineffectiveness,
switch to epinephrine.
5.4.8. In some patients with beta-adrenergic
blocking agents, it may be necessary
to increase the dose of epinephrine
rapidly: a first bolus of 100 µg,
followed when necessary by 1 mg or
even 5 mg, at 1 to 2 min intervals. If
not efficient, glucagons could be
effective (1 to 2 mg intravenously,
repeated every 5 min).
5.4.9. In case of hypotension, resistant to
high doses of epinephrine, various
other vasoconstrictor drugs can be
tried, as norepinephrine (starting with
0.1 µg·kg-1·min-1).
5.5. In case of cardiac arrest (grade IV) (E):
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5.5.1. External cardiac massage
5.5.2. Epinephrine: intravenous bolus of 1
mg every 1 to 2 min, or even 5 mg
bolus after the third injection. The
cumulative dose can reach 50 even
100 mg.
5.5.3. Follow the usual resuscitation
measures for cardio-circulatory
insufficiency
5.6. Additional secondary treatment in severe cases
(E) :
5.6.1. Corticosteroids may be given to decrease
delayed manifestations: administer
hydrocortisone hemisuccinate, 200 mg
intravenously every six hours.
5.6.2. Intensive monitoring must be assured
for at least 24 hours, due to the risk of
unstable blood pressure.
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